Aptabio Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Yongin Korea, Republic of (2009)

Organization Overview

First Clinical Trial
2018
NCT03694041
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Aptabio Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

apx-115 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Nephropathies (Phase 2)

Kidney Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1